Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTAI BioXcel Therapeutics	$1.90 -1.6%	$1.64	$1.17 ▼ $21.92	$11.69M	0.04	1.22 million shs	264,251 shs
CARM Carisma Therapeutics	$0.40 -2.0%	$0.31	$0.14 ▼ $1.38	$16.84M	1.92	3.72 million shs	487,747 shs
IXHL Incannex Healthcare	$0.21 +0.4%	$0.20	$0.08 ▼ $3.12	$6.16M	7.47	15.05 million shs	88.33 million shs
TLPH Talphera	$0.46 +2.7%	$0.49	$0.43 ▼ $1.19	$9.25M	-0.11	70,821 shs	61,182 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTAI BioXcel Therapeutics	-3.06%	+4.97%	+3.26%	+29.25%	-88.69%
CARM Carisma Therapeutics	-2.71%	+0.87%	+103.71%	+124.43%	-65.65%
IXHL Incannex Healthcare	+0.62%	-2.50%	+17.29%	-74.94%	-92.40%
TLPH Talphera	-0.43%	+0.61%	-9.22%	-5.53%	-50.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTAI BioXcel Therapeutics	4.521 of 5 stars	3.3	4.0	4.5	3.4	1.7	0.6
CARM Carisma Therapeutics	2.3525 of 5 stars	3.2	2.0	0.0	2.9	1.7	0.6
IXHL Incannex Healthcare	0.3004 of 5 stars	0.0	4.0	0.0	0.6	0.8	0.0
TLPH Talphera	1.9295 of 5 stars	3.8	3.0	0.0	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTAI BioXcel Therapeutics	2.67	Moderate Buy	$42.60	2,142.11% Upside
CARM Carisma Therapeutics	2.43	Hold	$1.93	387.34% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
TLPH Talphera	3.50	Strong Buy	$5.00	979.91% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTAI BioXcel Therapeutics	$2.27M	5.07	N/A	N/A	($30.01) per share	-0.06
CARM Carisma Therapeutics	$19.63M	0.84	N/A	N/A	($0.67) per share	-0.59
IXHL Incannex Healthcare	$98K	63.16	N/A	N/A	$0.18 per share	1.17
TLPH Talphera	$650K	14.60	N/A	N/A	$0.47 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTAI BioXcel Therapeutics	-$59.60M	-$13.55	N/A	N/A	N/A	-2,163.18%	N/A	-83.80%	8/5/2025 (Estimated)
CARM Carisma Therapeutics	-$60.48M	-$1.56	N/A	N/A	N/A	-254.28%	N/A	-137.38%	8/6/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	N/A
TLPH Talphera	-$13M	-$0.45	N/A	N/A	N/A	N/A	-130.28%	-59.25%	8/13/2025 (Estimated)

Latest IXHL, CARM, BTAI, and TLPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	BTAI BioXcel Therapeutics	-$2.30	N/A	N/A	N/A	$0.21 million	N/A
5/15/2025	Q3 2025	IXHL Incannex Healthcare	-$0.46	-$0.24	+$0.22	-$0.20	$0.16 million	$0.10 million
5/13/2025	Q1 2025	CARM Carisma Therapeutics	-$0.17	-$0.22	-$0.05	-$0.22	$2.47 million	$3.65 million
5/12/2025	Q1 2025	BTAI BioXcel Therapeutics	-$2.72	-$1.50	+$1.22	-$1.50	$0.35 million	$0.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTAI BioXcel Therapeutics	N/A	1.48	1.45
CARM Carisma Therapeutics	N/A	1.34	1.34
IXHL Incannex Healthcare	N/A	2.12	2.12
TLPH Talphera	N/A	3.11	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTAI BioXcel Therapeutics	30.68%
CARM Carisma Therapeutics	44.27%
IXHL Incannex Healthcare	0.43%
TLPH Talphera	37.67%

Insider Ownership

Company	Insider Ownership
BTAI BioXcel Therapeutics	21.20%
CARM Carisma Therapeutics	12.57%
IXHL Incannex Healthcare	15.49%
TLPH Talphera	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTAI BioXcel Therapeutics	90	6.06 million	4.77 million	Optionable
CARM Carisma Therapeutics	20	41.79 million	36.54 million	No Data
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
TLPH Talphera	19	20.50 million	19.85 million	Optionable

IXHL, CARM, BTAI, and TLPH Headlines

Recent News About These Companies

talphera receives extension to meet nasdaq listing requirements

June 7, 2025 | investing.com

Talphera Granted Extension for Nasdaq Compliance

June 5, 2025 | tipranks.com

Talphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 17, 2025 | finanznachrichten.de

Earnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025

May 16, 2025 | uk.investing.com

Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call Transcript

May 16, 2025 | msn.com

Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing

May 15, 2025 | msn.com

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | prnewswire.com

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

May 7, 2025 | prnewswire.com

All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy

May 7, 2025 | msn.com

Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?

April 5, 2025 | msn.com

Talphera reports Q4 EPS (7c) vs. (25c) last year

April 1, 2025 | markets.businessinsider.com

Talphera, Inc. (NASDAQ:TLPH) Q4 2024 Earnings Call Transcript

April 1, 2025 | msn.com

Talphera announces agreement with FDA to reduce NEPHRO CRRT study size

April 1, 2025 | markets.businessinsider.com

Talphera Reports 2024 Financial Results and Study Update

March 31, 2025 | tipranks.com

Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad

March 31, 2025 | msn.com

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 31, 2025 | prnewswire.com

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

March 31, 2025 | prnewswire.com

7TLPH : Earnings Outlook For Talphera

March 28, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL, CARM, BTAI, and TLPH Company Descriptions

BioXcel Therapeutics NASDAQ:BTAI

$1.90 -0.03 (-1.55%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$1.87 -0.03 (-1.58%)

As of 07/7/2025 06:23 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Carisma Therapeutics NASDAQ:CARM

$0.40 -0.01 (-1.99%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$0.40 +0.01 (+1.27%)

As of 07/7/2025 07:54 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Incannex Healthcare NASDAQ:IXHL

$0.21 +0.00 (+0.43%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$0.22 +0.01 (+2.71%)

As of 07/7/2025 07:59 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Talphera NASDAQ:TLPH

$0.46 +0.01 (+2.66%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$0.48 +0.02 (+4.75%)

As of 07/7/2025 07:13 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time